DYN 35.14 Dyne Therapeutics, Inc.
| Range: | 6.4-47.45 | Vol Avg: | 1273325 | Last Div: | 0 | Changes: | 1.11 |
| Beta: | 1.05 | Cap: | 3.38B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Sep 17 2020 | Empoloyees: | 152 | ||
| CUSIP: | 26818M108 | CIK: | 0001818794 | ISIN: | US26818M1080 | Country: | US |
| CEO: | Mr. John G. Cox M.B.A. | Website: | https://www.dyne-tx.com | ||||
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Stock Details
Positive 0.41
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc. (DYN) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / September 16, 2024 / Bronstein, Gewirtz & Grossman, LLC i...
accesswire.com·Mon Sep 16 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow